A total of 89 patients with active UC from January 2012 to June 2013 were selected and randomly divided into 46 patients in the mesalazine group and 43 patients in the sulfasalazine (SASP) group.
89 patients with active UC from January 2012 to June 2013 were randomly divided into mesalazine group (46 cases) and sulfasalazine (SASP) group (43 cases).